Related Experiment Video
Updated: Sep 22, 2025
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy
Giulia Ricci1, Luca Bello2, Francesca Torri1
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Introduction:
Duchenne muscular dystrophy (DMD) is a devastatingly severe genetic muscle disease characterized by childhood-onset muscle weakness, leading to loss of motor function and premature death due to respiratory and cardiac insufficiency.
Discussion:
In the following three and half decades, DMD kept its paradigmatic role in the field of muscle diseases, with first systematic description of disease progression with ad hoc outcome measures and the first attempts at correcting the disease-causing gene defect by several molecular targets. Clinical trials are critical for developing and evaluating new treatments for DMD.
Conclusions:
In the last 20 years, research efforts converged in characterization of the disease mechanism and development of therapeutic strategies. Same effort needs to be dedicated to the development of outcome measures able to capture clinical benefit in clinical trials.
Insights
Duchenne muscular dystrophy (DMD) research has advanced significantly, focusing on disease mechanisms and gene correction. Future efforts must prioritize developing outcome measures for effective clinical trials in DMD.
Area of Science:
- Neurology
- Genetics
- Biomedical Research
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic muscle disorder.
- Characterized by childhood-onset muscle weakness, leading to functional loss and premature death from respiratory and cardiac issues.
Purpose of the Study:
- To review the historical progression of Duchenne muscular dystrophy research.
- To highlight the importance of clinical trials and outcome measures in developing DMD treatments.
Main Methods:
- Systematic review of research efforts in Duchenne muscular dystrophy.
- Analysis of historical data on disease progression and therapeutic strategies.
Main Results:
- DMD has served as a model disease for muscle disorders.
- Significant progress has been made in understanding disease mechanisms and gene-targeting therapies.
- Clinical trials are essential for evaluating new DMD treatments.
Conclusions:
- Continued focus on developing robust outcome measures is crucial for clinical trials.
- Advancing therapeutic strategies requires parallel development in outcome assessment.
